Trial · NCT06818266
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
NCT06818266, Phase 3, Recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease. Trials, record NCT06818266. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06818266
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
- NCT number
- NCT06818266
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 130 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Sickle Cell Disease, Acute Chest Syndrome
- Interventions
- Tocilizumab (RoActemra®, 20 mg/mL)., Placebo (NaCl 0.9%)
- First posted
- 2025-02-10
- Last updated
- 2026-06-24
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to successful weaning from both supplemental oxygen and any respiratory support | During hospitalization for ACS, from randomization until day 28 after randomization | Successful weaning from both supplemental oxygen and any respiratory support, defined as SpO2 ≥ 95% without oxygen during the next 24 hours, and spontaneous breathing without any respiratory support (non-invasive or invasive) during the next 48 hours |
| Secondary | Adverse events during hospitalization and within 3 months following tocilizumab or placebo injection | Within 3 months after randomization | Severe and not severe adverse events (including hypertension, hypersensitivity reactions, hypokalemia, neutropenia, thrombocytopenia, infections, pulmonary embolism/thrombosis, hepatic cytolysis, organ failure) |
| Secondary | Time to discharge | From the date of randomization until the date of end of hospitalization, assessed up to 3 months | Length of hospital stay |
| Secondary | Mortality | Within 3 months after randomization | Mortality |
| Secondary | Need for transfusion | From the date of randomization until the date of end of hospitalization, assessed up to 3 months | Need for red blood cell transfusion |
| Secondary | Total number of red blood cell units received | From the date of randomization until the date of end of hospitalization, assessed up to 3 months | Total number of red blood cell units received |
| Secondary | Need for non-invasive ventilation (for patients without ventilatory support at inclusion) | From the date of randomization until the date of end of hospitalization, assessed up to 3 months | Need for non-invasive ventilation (high flow nasal oxygen, continuous positive airway pressure, or bilevel non-invasive ventilation), for patients without ventilatory support at inclusion |
| Secondary | Need for invasive ventilation (for patients without invasive ventilation at inclusion) | From the date of randomization until the date of end of hospitalization, assessed up to 3 months | Need for invasive ventilation, for patients without invasive ventilation at inclusion |
| Secondary | Readmission for vaso-occlusive crisis or ACS within 3 months following tocilizumab or placebo injection | Within 3 months after randomization | Readmission for vaso-occlusive crisis or ACS within 3 months following tocilizumab or placebo injection |
| Secondary | C-reactive protein (CRP), procalcitonin (PCT), plasma and sputum IL-6 levels 48 (+/- 12) hours after tocilizumab or placebo injection | 48 (+/- 12) hours after tocilizumab or placebo injection | C-reactive protein (CRP), procalcitonin (PCT), plasma and sputum IL-6 levels 48 (+/- 12) hours after tocilizumab or placebo injection |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06818266
GET https://conductscience.org/api/trials/v1/NCT06818266/registered